Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this clinical trial is to find out the effect of epirubicin with estramustine phosphate and celecoxib on PSA and objective response in patients with hormone resistant prostate cancer as well as evaluating the toxicity, quality of life of this combination. Celecoxib is an FDA approved drug to treat arthritis. Epirubicin, alone or with estramustine phosphate has been used in the treatment of hormone resistant prostate cancer. These drugs have demonstrated evidences of tumor blood vessel suppression and combination of these three drugs could possibly arrest further tumor growth or even make the tumor decrease in size.
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria:
NOTE: Patients who have not undergone bilateral orchiectomy must continue LHRH agonist therapy (e.g., depot leuprolide or goserelin) while receiving this protocol therapy.
Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
Loading...
Central trial contact
Basil Kasimis, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal